Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 5/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30112386 | 0.95 | IKZF2 (0.41) | CXCR3TLR9TLR8TLR7SIGMAR1 | |
| SCHEMBL24881321 | 0.85 | CRBN (0.39) | CXCR3 | |
| SCHEMBL24881322 | 0.81 | TLR9 (0.36) | TLR9TLR8TLR7SIGMAR1JAK2 | |
| SCHEMBL24125612 | 0.78 | CRBN (0.54) | JAK2SYK | |
| SCHEMBL31382219 | 0.78 | CRBN (0.54) | JAK2SYK | |
| SCHEMBL24881330 | 0.77 | HTR2C (0.42) | SIGMAR1 | |
| SCHEMBL27073454 | 0.77 | HTR2C (0.42) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL31382362 | 0.77 | CRBN (0.52) | JAK2SYK | |
| Hydrochloric Acid SCHEMBL25173203 | 0.77 | CRBN (0.52) | JAK2SYK | |
| SCHEMBL27039451 | 0.77 | DDB1 (0.54) | JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | C4 THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| CN-117940414-A | Compounds for targeting IRAK4 protein degradation | 渤健马萨诸塞州股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | CXCR3 4500/4885TLR9 224/4885TLR8 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.